Phenotyping of 76 human bladder tumors with a panel of monoclonal antibodies: Correlation between pathology, surface immunofluorescence and DNA content

Hijazi, A; Devonec, M.; Bouvier, Raymonde; Escourrou, Ghislaine; Longin, Arlette; Perrin, Paul B.; Revillard, Jean‐Pierre

doi:10.1016/0277-5379(89)90120-x

Cited by 14 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Saturation of antigenic sites on HUVEC was obtained with MoAb concentration of 100 ng/ml, indicating high affinity (: 10-to M-1). The 6D1 MoAb which binds to bladder cancer cells but not to blood cells or EC was used as a negative isotypematched control (19). A rabbit polyclonal antibody directed against human von Willebrand factor (20) and a rabbit polyclonal antibody directed against human placental thrombomodulin (21) were used as endothelial cell-associated reagents.…”

Section: Antibodiesmentioning

confidence: 99%

Rapid Isolation of Human Endothelial Cells from Whole Blood Using S-Endo1 Monoclonal Antibody Coupled to Immuno-Magnetic Beads: Demonstration of Endothelial Injury after Angioplasty

et al. 1992

View full text Add to dashboard Cite

SummaryThe presence in whole blood of circulating endothelial cells (EC) has been a subject of debate for many years. It could represent a good marker of vessel injury. We demonstrate here that human endothelial cells can be directly isolated and identified in circulating blood by means of an endothelial cell specific monoclonal antibody, S-Endol, coupled to micromagnetic beads. The specificity and efficacy of the assay were established using normal blood samples with cultured EC added. Specific rosettes formed between EC and beads could subsequently be isolated with a magnet. The rosetted cells were recovered with a yield >80%. Their endothelial origin was confirmed by the positive labelling of von Willebrand factor and thrombomodulin, as well as the presence of Weibel-Palade bodies. We applied this method to demonstrate significantly increased levels of EC in venous and arterial human blood samples in patients undergoing heart catheterization. This new whole blood immuno-separation method may be useful in determining endothelial cell injury in vascular disorders.

show abstract

Section: Antibodiesmentioning

confidence: 99%

Rapid Isolation of Human Endothelial Cells from Whole Blood Using S-Endo1 Monoclonal Antibody Coupled to Immuno-Magnetic Beads: Demonstration of Endothelial Injury after Angioplasty

et al. 1992

View full text Add to dashboard Cite

show abstract

“…This antibody also reacts moderately with smooth muscle cells. The 6D1 MAb that binds to bladder cancer cells but not blood cells or ECs was used as a negative isotype-matched control (17).…”

Section: Blood Samplesmentioning

confidence: 99%

Evidence for the Expression of Urokinase-type Plasminogen Activator by Human Venous Endothelial Cells In Vivo

Camoin

Pannell²,

Anfosso³

et al. 1998

Thromb Haemost

View full text Add to dashboard Cite

SummaryEndothelial cells (ECs) in culture synthesize and secrete urokinase-type plasminogen activator (u-PA), but the normal vascular endothelium is believed to synthesize only tissue plasminogen activator (t-PA), which is thought to be responsible for intravascular fibrinolysis. More recently, animal studies have shown that the biological role of u-PA in fibrinolysis has been underestimated, prompting a re-examination of its synthesis by the endothelium. In this study, we investigated whether u-PA was synthesized by non-atherosclerotic endothelial cells in vivo by testing ECs dislodged by venipuncture from 12 normal volunteers and 17 patients admitted for plasmapheresis. The ECs were isolated with an anti-endothelial monoclonal antibody coupled to immunomagnetic beads and characterized by morphology and by labelling for vWF, CD31, and UEA-1 binding. U-PA antigen was found in 50% of the ECs from the normal subjects and in 60% of those from patients. U-PA enzymatic activity on zymograms was detected in 50% of the normal samples and 60% of the patient samples, with the latter being more frequently and more strongly positive. U-PA mRNA was found in all the normal and patient samples tested. The results indicate that u-PA is synthesized by the venous endothelium in vivo but that its expression is highly variable.

show abstract

“…These antibodies have been successfully used to stain frozen and deparaffinized sections by indirect immunoperoxidase staining. Their reactivity has been evaluated by the present authors [2] and by other groups [10] in > 150 specimens. The epitope recognized by these antibodies is preferentially expressed on high-stage, highgrade, and aneuploid tumors; 80°70 of invasive or grade III tumors are stained as compared with 20% of lowgrade, noninvasive tumors.…”

Section: Monoclonal Antibodies Used In Urinary Cytologymentioning

confidence: 99%

“…The epitope recognized by these antibodies is preferentially expressed on high-stage, highgrade, and aneuploid tumors; 80°70 of invasive or grade III tumors are stained as compared with 20% of lowgrade, noninvasive tumors. In flow cytometry, G4 reacts preferentially with tumors exhibiting a bimodal DNA profile [10]. Both antibodies cross-react with umbrella cells (normal urothelium), granulocytes, intestinal goblet cells, and proximal renal tubules.…”

Section: Monoclonal Antibodies Used In Urinary Cytologymentioning

confidence: 99%

Monoclonal antibodies in bladder cancer cytology

Chopin

Laurent

1991

World J Urol

View full text Add to dashboard Cite

Conventional urinary cytology is the only routine noninvasive test accepted for the early detection and follow-up of bladder cancer. However, accuracy is achieved only in high-grade tumors and the method requires an experienced cytopathologist. Hybridoma technology has been developed to identify molecules or antigenic epitopes associated with malignant transformation. This report discusses the various monoclonal antibodies that have been generated against transitional-cell carcinoma (TCC) of the bladder and can be used to detect exfoliated cancer cells in urine. Several antibodies that recognize epitopes related to Lewis X carbohydrate molecules react with TCC cells of various grades, with the detection rate ranging from 70°7o-90°7o. Further studies are required to standardize the methodology and to determine the value of immunocytology in the management of bladder cancer patients. However, this approach shows great promise for improving diagnostic accuracy and for pedicting biological aggresiveness and response to therapy.Urinary cytology was the first noninvasive method for diagnosing transitional-cell carcinoma of the bladder (TCC) [18]. Cytologic examination of voided urine or bladder washings has given variable results the for initial diagnosis and follow-up of patients with urothelial lesions [3]. Most false-negative results are associated with low-grade tumors [23]. In a study of a urology clinic population [20], the diagnostic yield was 34070 for grade I, 75% for grade II, and 94°7o for grade III tumors. In contrast, in a study of a highly selected group of patients by an experienced cytopathologist [16], the diagnostic yield was 70°70 for grade I, 98% for grade II, and 100070 for invasive grade III tumors and carcinoma in situ (CIS). The overall specificity in the former study was 95°7o as compared with 90°70 in the latter study, showing that the improvement in diagnosis was achieved at the cost of a higher false-positive rate.Requests for reprints." Dominique K. Chopin, Service d'Urologie, H6pital Henri Mondor, 1=-94000 Creteil, France Current knowledge of the natural history and biology of urothelial tumors points to the need for accurate, noninvasive, cost-effective methods of detecting bladder tumor markers, with a view to improving diagnostic accuracy and predicting biological behavior and response to treatment. Indeed, with the widespread adaption of intravesical prophylaxis of superficial bladder tumors using chemotherapy or biological response modifiers (bacille Calmette Gu~rin) and the trend towards conservative management, such tools are becoming essential. In addition, although some patients with superficial disease may benefit from simple surveillance or prophylaxis, specific patient subgroups at the other end of the spectrum may require immediate radical locoregional therapy.Urinary cytology might provide information closely reflecting field changes associated with malignant transformation in the urinary bladder. Several approaches are currently being used in an attempt to improve the biolog...

show abstract

Phenotyping of 76 human bladder tumors with a panel of monoclonal antibodies: Correlation between pathology, surface immunofluorescence and DNA content

Cited by 14 publications

References 12 publications

Rapid Isolation of Human Endothelial Cells from Whole Blood Using S-Endo1 Monoclonal Antibody Coupled to Immuno-Magnetic Beads: Demonstration of Endothelial Injury after Angioplasty

Rapid Isolation of Human Endothelial Cells from Whole Blood Using S-Endo1 Monoclonal Antibody Coupled to Immuno-Magnetic Beads: Demonstration of Endothelial Injury after Angioplasty

Evidence for the Expression of Urokinase-type Plasminogen Activator by Human Venous Endothelial Cells In Vivo

Monoclonal antibodies in bladder cancer cytology

Contact Info

Product

Resources

About